[Identification of GPAT1-dependent mitochondrial metabolism as a novel therapeutic target for AML]

Area of Science:

• Biochemistry
• Oncology
• Cell Biology

Background:

• Cancer cells exhibit altered metabolism, crucial for malignancy.
• Acute myeloid leukemia (AML) shows reprogrammed glycerol-3-phosphate (G3P) metabolism.

Purpose of the Study:

• To identify novel therapeutic targets for AML by screening metabolites.
• To investigate the role of glycerol-3-phosphate acyltransferases (GPATs) in AML.

Main Methods:

• Metabolite screening of AML cells and normal hematopoietic stem/progenitor cells (HSPCs).
• Gene silencing of GPAT1 and assessment of its impact on AML cell growth.
• Mitochondrial function analysis (fusion, fission, oxidative phosphorylation).
• In vivo studies using a GPAT1 inhibitor on normal hematopoiesis.

Main Results:

• Glycerol-3-phosphate (G3P) metabolism is reprogrammed in AML.
• GPAT1 is highly expressed in AML cells, and its silencing inhibits AML cell growth.
• GPAT1 inhibition promotes mitochondrial fission and reduces oxidative phosphorylation (OXPHOS) in AML.
• A GPAT1 inhibitor suppressed AML proliferation and mitochondrial metabolism without affecting normal hematopoiesis in vivo.

Conclusions:

• GPAT1 plays a critical role in AML cell proliferation and metabolism.
• Targeting GPAT1 represents a potential therapeutic strategy for AML.
• GPAT1 inhibition selectively targets leukemia-specific metabolism, sparing normal hematopoietic stem/progenitor cells.